热门资讯> 正文
InMed Pharmaceuticals GAAP每股收益为-0.73美元
2026-05-07 06:08
- InMed Pharmaceuticals press release (INM): Q3 GAAP EPS of -$0.73.
- As of March 31, 2026, the Company's cash, cash equivalents and short-term investments were $5.2 million, which compares to $10.8 million on June 30, 2025.
More on InMed Pharmaceuticals
- InMed Pharma gets Nasdaq non-compliance notice
- Financial information for InMed Pharmaceuticals
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。